Annexon, Inc. ANNX
4.01 USD -0.19 (-4.42%)
Nov 12, 2026, 12:35 PM EST
3.98 Day range 4.17
2.54 52-week range 7.18
- YTD
- -20.22%
- 1 year
- +41.02%
News
benzinga.com Annexon Q3 EPS $(0.25) Beats $(0.28) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 32.43 percent increase over losses of $(0.37) per…
globenewswire.com Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission…
defenseworld.net Annexon Eyes Q4 2026 Phase III Readout for Vision-Preserving GA Drug Annexon (NASDAQ: ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of…
benzinga.com Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026.…
benzinga.com Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded Global-E and raised Annexon’s target; targets fell for Truist, Ameriprise, Lyft, A.O. Smith and Hudson Pacific.
benzinga.com HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25 HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Humana (NYSE:HUM) stock moved upwards by 16.2% to $450.0 during Friday's pre-market session. The market value of their outstanding shares is at $46.4 billion. XORTX Therapeutics (NASDAQ:XRTX)…
benzinga.com JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15 JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $15.- benzinga.com JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14 JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
- benzinga.com Annexon Q2 EPS $(0.28) Misses $(0.24) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 17.65 percent increase over losses of $(0.34)…
benzinga.com Annexon Adds Month 24 Dual Primary Endpoint To Complement Current Month 15 Primary Endpoint In Phase 3 ARCHER II Trial And Launches OLE Study Of Vonaprument For Treatment Of Dry AMD With Geographic Atrophy Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…
benzinga.com Annexon Reports Early Strength Improvement And Clinically Meaningful Disability Reduction With Tanruprubart In First Ten US And European Guillain-Barré Syndrome Patients From Ongoing FORWARD Study Early Outcomes Reinforce the Consistency and Reproducibility of Tanruprubart Treatment Effect Previously Demonstrated in Phase 3 and Real-World Evidence Studies Potential to Become the First Approved…
benzinga.com Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million…- benzinga.com Citizens Initiates Coverage On Annexon with Market Underperform Rating, Announces Price Target of $3 Citizens analyst Jonathan Wolleben initiates coverage on Annexon (NASDAQ:ANNX) with a Market Underperform rating and announces Price Target of $3.
benzinga.com Needham Maintains Buy on Annexon, Raises Price Target to $25 Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $11 to $25.- benzinga.com Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people…
- benzinga.com Goldman Sachs Initiates Coverage On Annexon with Neutral Rating, Announces Price Target of $7 Goldman Sachs analyst Salveen Richter initiates coverage on Annexon (NASDAQ:ANNX) with a Neutral rating and announces Price Target of $7.
benzinga.com Annexon Q1 EPS $(0.23) Beats $(0.29) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.29) by 20.69 percent. This is a 37.84 percent increase over losses of $(0.37) per…
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…- benzinga.com Annexon Q4 EPS $(0.28) Beats $(0.32) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.32) by 11.11 percent. This is a 15.15 percent increase over losses of $(0.33) per…
benzinga.com Alpha Buying: Managing Biotech Risk With Insider Clues - benzinga.com Annexon Highlights 2026 Milestones With Tanruprubart MAA Filing, Vonaprument Phase 3 Data In Dry AMD, ANX1502 Proof‑of‑Concept Readout, Snd Strong Cash Position Funding Into 2027 Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome (GBS); BLA Submission with U.S./European Data Planned in 2026Vonaprument Pivotal Phase 3…
- benzinga.com Annexon Submits Marketing Authorization Application To EMA For Tanruprubart For Treatment Of Guillain-Barré Syndrome Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of CareBLA Submission with U.S./European Data from FORWARD Trial Planned in 2026BRISBANE, Calif., Jan. 08, 2026…
- benzinga.com Chardan Capital Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $16 Chardan Capital analyst Daniil Gataulin initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $16.
- benzinga.com Clear Street Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $17 Clear Street analyst Bill Maughan initiates coverage on Annexon (NASDAQ:ANNX) with a Buy rating and announces Price Target of $17.
- benzinga.com Wells Fargo Maintains Overweight on Annexon, Raises Price Target to $27 Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $27.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session - benzinga.com HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $14 Price Target HC Wainwright & Co. analyst Ananda Ghosh reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $14 price target.
- benzinga.com Annexon Q2 EPS $(0.34) Beats $(0.37) Estimate Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 7.1 percent. This is a 47.83 percent decrease over losses of $(0.23) per…
- benzinga.com Annexon Announces That The European Medicines Agency Has Selected Vonaprument To Participate In The Product Development Coordinator Pilot New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence PlanningVonaprument Selected by EMA as One of ~20…
benzinga.com Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
- benzinga.com Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- benzinga.com Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.
- benzinga.com Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24…
- benzinga.com Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 221 companies hit new 52-week lows.
- benzinga.com Why Dollar Tree Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers Beamr Imaging Ltd. (NASDAQ: BMR) shares climbed 211.6% to $6.86 after NVIDIA announced the release of NVENC Video Codec SDK 12.1 showcasing the integration with Beamr CABR.
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2023
- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022
- benzinga.com 79 Biggest Movers From Yesterday Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying…
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's morning session, 234 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 78 companies set new 52-week lows.